MicroRNA in disease regulation
MicroRNA in disease regulation is a research topic within Cancer Research. Science Explorer counts 66k research works in it since 1951. 25.5% of them reached the world's top 10% most cited for their field and year.
This cluster of papers focuses on the role of microRNAs in gene expression regulation, particularly in the context of cancer development and progression. It covers topics such as microRNA biogenesis, targeting specificity, biomarker potential, and therapeutic applications in cancer treatment.
- MicroRNA
- Gene Expression
- Cancer
- Regulation
- Biomarkers
- Biogenesis
- Targeting
- Therapeutics
- Metastasis
- Dysregulation
- Research works
- 66k fractional, since 1951
- In the world top 10%
- 17k per year above
- Top-10% rate
- 25.5% share of its works in the world top 10%
- Growth, 2013–17 → 2018–22
- +46% the tick is no change
Which countries lead MicroRNA in disease regulation research?
By volume, China and the United States publish the most (7.9k and 1.8k works in 2022–2025).
By volume, 2022–2025
- 1 China 7.9k works
- 2 United States 1.8k works
- 3 Iran 713 works
- 4 India 705 works
- 5 Italy 431 works
- 6 Japan 336 works
- 7 Germany 326 works
- 8 South Korea 306 works
- 9 Egypt 257 works
- 10 Spain 247 works
How concentrated that is
The same countries as shares of everything the list above accounts for. A node where two countries do two thirds of the work and one spread evenly across twelve read alike as a ranking and not at all alike here.
Shares of the rows listed above, not of the whole node.
Which institutions lead MicroRNA in disease regulation research?
By volume in 2022–2025, Central South University publishes the most MicroRNA in disease regulation research, followed by Nanjing Medical University and Sun Yat-sen University.
By volume, 2022–2025
- 1 Central South University China 96 works
- 2 Nanjing Medical University China 92 works
- 3 Sun Yat-sen University China 80 works
- 4 China Medical University China 74 works
- 5 Sichuan University China 71 works
- 6 Chinese Academy of Medical Sciences & Peking Union Medical College China 69 works
- 7 Shanghai Jiao Tong University China 68 works
- 8 Huazhong University of Science and Technology China 66 works
- 9 Zhejiang University China 60 works
- 10 Harbin Medical University China 59 works
Who are the leading researchers in MicroRNA in disease regulation?
The most-cited researchers publishing on MicroRNA in disease regulation include Amirhossein Sahebkar and Chad A. Mirkin.
- 1 Amirhossein Sahebkar 5.6k citations
- 2 Chad A. Mirkin 4.6k citations
Ranked by citations received across their whole record, among researchers with at least three works on this topic.
Where is MicroRNA in disease regulation research done?
The largest centres of MicroRNA in disease regulation research in 2022–2025 are Beijing (China), Shanghai (China), Guangzhou (China) and Wuhan (China). Among places with at least 20 works in it, it is an unusually large share of all research in Nantong and Zunyi.
Largest cities, 2022–2025
Where it is the local speciality
- NantongCN · 87.6 works12×
- ZunyiCN · 33.4 works11×
Location quotient: how much more of its research is in MicroRNA in disease regulation than the world average.
Where is the best place to study MicroRNA in disease regulation?
Among universities, judged by research, Tabriz University of Medical Sciences, China Medical University and Shahid Beheshti University of Medical Sciences score highest, combining excellence, specialisation, size, growth and international reach. Research strength is one signal when choosing where to study; it does not measure teaching.
One dot per university in the table below. The upper left is the interesting corner: small places doing unusually strong work.
| # | University | Score | Top 10% | Specialisation | Works | Growth |
|---|---|---|---|---|---|---|
| 1 | Tabriz University of Medical Sciences Iran | 75.1 | 26.8% | 14.3× | 50 | +1813.3% |
| 2 | China Medical University China | 74.9 | 26.0% | 15.0× | 74 | +183.5% |
| 3 | Shahid Beheshti University of Medical Sciences Iran | 72.7 | 22.8% | 10.1× | 54 | +815.0% |
| 4 | Guangzhou Medical University China | 70.2 | 22.6% | 10.2× | 42 | +238.3% |
| 5 | Nanjing Medical University China | 70.0 | 24.3% | 11.9× | 92 | +90.3% |
| 6 | Shandong First Medical University China | 69.3 | 23.7% | 9.9× | 39 | +394.8% |
| 7 | Xuzhou Medical College China | 69.0 | 24.1% | 11.6× | 37 | +259.5% |
| 8 | Dalian Medical University China | 68.7 | 25.4% | 11.1× | 32 | +208.5% |
| 9 | Mashhad University of Medical Sciences Iran | 68.3 | 24.8% | 9.3× | 34 | +1669.0% |
| 10 | Shanxi Medical University China | 67.3 | 19.9% | 12.8× | 42 | +256.5% |
Universities only. Score blends excellence (30%), specialisation (25%), size (20%), growth (15%) and international reach (10%), 2015–2022; growth compares 2010–14 with 2015–19.
Is MicroRNA in disease regulation research growing?
Output in 2018–2022 was 46% higher than in 2013–2017, peaking in 2020. The fastest-growing topics are MicroRNA in disease regulation.
The same series as a ribbon — one cell per year, darker for more. The line above answers how much; this answers when.
Which topics inside it are moving
Growth and decline on one axis around a shared zero. Two lists side by side hide the thing that matters: whether the growth dwarfs the decline, or the other way round.